Načítá se...
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
Insertion mutations in exon 20 (Ex20ins) of the epidermal growth factor receptor (EGFR) gene are the largest class of EGFR mutations in non-small cell lung cancer (NSCLC) for which there are currently no approved targeted therapies. NSCLC patients with these mutations do not respond to clinically ap...
Uloženo v:
| Vydáno v: | Pharmgenomics Pers Med |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7955704/ https://ncbi.nlm.nih.gov/pubmed/33727854 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PGPM.S242045 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|